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Objective: To determine the effect of adjunctive quetiapine therapy on the sleep architecture 
of patients with bipolar or unipolar depression.
Methods: This is a prospective, single-blind, repeated measures polysomnographic study. Sleep 
architecture was analyzed by overnight polysomnography, and subjective sleep quality was 
measured using the Pittsburgh Sleep Quality Index. The Hamilton Rating Scale for Depression, 
Montgomery Asberg Depression Rating Scale, Young Mania Rating Scale, and Clinical Global 
Impression-Severity Scale were employed to quantify changes in illness severity with adjunctive 
quetiapine treatment. Polysomnographs and clinical measures were administered at baseline, 
after 2–4 days of treatment, and after 21–28 days of quetiapine treatment. The average dose of 
quetiapine was 155 mg, ranging from 100–200 mg.
Results: Adjunctive quetiapine therapy did not significantly alter sleep efficiency, sleep conti-
nuity, or Pittsburgh Sleep Quality Index scores. Respiratory Disturbance Index and percentage 
of total time in rapid eye movement (REM) sleep significantly decreased and the percentage of 
total time in non-REM sleep, and duration of Stage 2 and non-REM sleep significantly increased 
after 2–4 days of quetiapine treatment. Illness severity significantly decreased over time.
Conclusions: Adjunctive quetiapine treatment alters sleep architecture in patients with major 
depressive disorder or bipolar disorder, which may partially explain its early antidepressant 
properties. Changes in sleep architecture are more robust and significant within two to four 
days of starting treatment.
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Introduction
Quetiapine is an atypical antipsychotic agent and is approved by the United States Food 
and Drug Administration to treat schizophrenia, major depressive disorder (MDD) 
and both manic and depressive episodes associated with bipolar disorder. The drug 
acts as an antagonist at serotonin (5-HT1A and 5-HT2), dopamine (D1 and D2), hista-
mine (H1), and adrenergic α1 and α2 receptors.1 Results from the BOLDER I and II 
studies, which were two large, multicenter, randomized, placebo-controlled trials, 
show that quetiapine is efficacious in the treatment of acute bipolar depression as 
monotherapy.2,3 These studies led to guidelines recommending quetiapine for use as 
first-line monotherapy treatment for bipolar depression.4 Use of an atypical antipsy-
chotic as an adjuvant therapy with selective serotonin reuptake inhibitors (SSRIs) has 
shown benefits in large trials of olanzapine use with fluoxetine.5,6 The use of quetiapine 
as an adjunctive therapy has been shown to be beneficial in smaller, open-label studies 
of patients with bipolar depressive episodes.7,8 Large, randomized placebo-controlled Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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trials have found the use of quetiapine as monotherapy, or in 
combination with another antidepressant, to be efficacious 
in the treatment of MDD.9–11
Patients with MDD and bipolar disorder frequently 
experience sleep disturbances.12 Poor sleep quality and/or 
quantity are observed in up to 90% of depressed patients.13 
Insomnia is a risk factor for development of major depres-
sive episodes and may precede the onset of depression in 
those with recurrent illness.14–16 Sleep disturbance is also a 
risk factor for suicide.17 Studies of sleep architecture using 
polysomnography (PSG) have demonstrated that sleep in 
depressed patients tends to be characterized by decreased 
sleep efficiency, a reduction of slow-wave sleep (SWS), and a 
disinhibition of rapid eye movement (REM) sleep, manifested 
by a shortening of REM sleep latency, an increase in REM 
length, and an increased REM density.18,19
Low doses of quetiapine alter the sleep architecture 
of healthy individuals.20,21 Somnolence is a side effect of 
quetiapine treatment, leading to prescription in an off-label 
fashion when this side effect is desired.22 The somnolence 
effect of quetiapine is thought to arise from its 5-HT2 and H1 
receptor blockade capabilities, similar to those of medications 
used as sedatives, including the antidepressants mirtazapine, 
trazodone, and trimipramine. Qualitative sleep studies using 
the Pittsburgh Sleep Quality Index (PSQI) have shown 
improvements in the sleep quality of depressed patients after 
initiation of quetiapine therapy.23,24
The effect of quetiapine on sleep architecture, measured 
by PSG, has not been studied in patients experiencing a major 
depressive episode. Clinical practice indicates that quetiapine 
has sedating properties, and its sedative effects may play an 
important role in restoring quality of sleep in patients with 
MDD or bipolar disorder who frequently experience sleep 
disturbances as part of their illness. We hypothesize that 
quetiapine alters the subjective sleep quality and PSG sleep 
architecture of patients with MDD or bipolar disorder. We 
expect that quetiapine will improve sleep efficiency, decrease 
sleep latency and duration of REM sleep, and increase the 
duration of SWS. If such changes occur and can be related 
to the improvement of depressive symptomatology, it is sug-
gested that part of quetiapine’s antidepressant effect may be 
achieved through its restoration of sleep architecture.
Methods
Study design
This was a four-week, single-blind, open-label, repeated 
measures PSG study of patients with MDD or bipolar disor-
der currently experiencing a major depressive episode, who 
received quetiapine fumarate treatment in addition to their 
current medication regime. Patients were recruited from a 
single-center, tertiary care mood disorders clinic. The study 
was approved by the Queen’s University Health Sciences 
and Affiliated Teaching Hospitals Research Ethics Boards 
as well as by the Health Canada Therapeutics Products 
Directorate.
Study population
Patients were recruited from inpatient and outpatient services 
for the evaluation and treatment of depression. All partici-
pants were 18 years of age or older and gave written informed 
consent. All patients had a Diagnostic and Statistical Manual 
of Mental Disorders, 4th Edition (DSM-IV) diagnosis of 
bipolar disorder (Type 1, Type 2, or not otherwise specified) 
or MDD, and were currently experiencing a major depres-
sive episode (Hamilton Depression Rating Scale-17 item 
[HDRS-17] $ 15, Young Mania Rating Scale [YMRS] # 8). 
Participants with a previous diagnosis of schizophrenia 
and/or current substance abuse (except caffeine and nicotine) 
were excluded. Prior antipsychotic use including quetiapine 
was allowed, but antipsychotics had to have been discontin-
ued at least one week prior to study initiation. Sleep aids, 
including over-the-counter hypnotics, were discontinued at 
least one week prior to study initiation, and changes to base-
line medications were not allowed in the three weeks prior 
to participation or during the study. Study participants were 
withdrawn from the study if they experienced significant side 
effects or withdrew consent.
Fifteen patients were enrolled in the trial. Four patients 
voluntarily withdrew from the study before completing a 
post-baseline PSG, two citing excessive sedation, one a 
post-menopausal bleed, and one a headache, and thus were 
not included in the completer analysis population. Therefore, 
only 11 patients were included in the analysis.
The completer population consisted of nine females and 
two males, with a mean age of 44.3 (± 9.1) years. Five patients 
had a diagnosis of MDD and six patients had a diagnosis of 
bipolar disorder. Ten of 11 patients were taking antidepres-
sants (five venlafaxine, one sertraline, two bupropion, one 
citalopram, and one a combination of bupropion and ven-
lafaxine). Two patients were taking lithium and topiramate 
as mood stabilizers. Five patients possibly took sedating 
medications during the trial; three were taking established 
regimens of regular benzodiazepines prescribed as anxiolyt-
ics (one lorazepam, one clonazepam, and one a combination 
of oxazepam and lorazepam) and two were taking regular 
trazodone prescribed as an antidepressant. One patient had Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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occasional sleep difficulties surrounding nocturnal priapism 
and another patient had obstructive sleep apnea and was being 
treated with continuous positive airway pressure.
Quetiapine treatment
Quetiapine was given in tablet form and taken at night near 
bedtime. An initial dose of 50 mg was given and the dose was 
titrated up over the course of the study, with drug tolerance 
as the primary influence on titration. The   average dose of 
quetiapine achieved was 155 mg, ranging from 100–200 mg. 
A fourth phase of the study, involving further titration of 
quetiapine to a target dose of 600 mg per day and PSG, 
PSQI, and mood scales at days 42–48 was optional, and is 
not included here due to poor participation (five of 11 patients 
of the completer group).
Clinical assessments
Patients were assessed at three time points, ie, baseline (before 
administration of study medication), and after 2–4 days and 
21–28 days of quetiapine treatment. Each clinical assessment 
consisted of the HDRS-17, Montgomery Asberg Depression 
Rating Scale (MADRS), YMRS, Clinical Global Impression 
Severity (CGI-S) scale, and participant-reported PSQI.
Polysomnography
Objective sleep architecture measurements were derived 
from PSG data of study participants at defined intervals 
throughout the study period. A baseline PSG was taken on 
the day before quetiapine administration began, then once 
during days 2–4, and once during days 21–28. On each of 
the three study nights, sleep PSGs were set up by a quali-
fied technician and recorded using the MediPalm Personal 
Recording Device (Braebon Corp., Ogdensburg, NY) while 
the patient slept at home. Patients were asked to retire and 
rise at their usual time. The standard overnight PSG sleep 
study included four electroencephalogram channels (C4-A1, 
C3-A2, O2-A1, O1-A2), electro-oculogram (two channels), 
submental electromyogram (EMG), pulse oximetry, oronasal 
airflow (oronasal thermistor), chest and abdominal movement 
(respiratory inductance plethysmography), and tibialis ante-
rior EMG. A position sensor was used to monitor position 
continuously (Ultima Body Position Sensor; Braebon Corp., 
Ogdensburg, NY). The overnight sleep routine was applied 
starting at around 1900 hours each study night. Recording 
began at approximately 2100 hours, and ran for eight hours 
continuously or until the participant rose in the morning. One 
of two certified PSG analysts, different from the technician 
setting up the PSG and blinded to study design and day of 
study, scored the sleep record in 30-second segments accord-
ing to the standardized criteria of Rechtschaffen and Kales,25 
using Pursuit Advanced Sleep System software (Braebon 
Corp., Ogdensburg, NY).
Sleep onset was defined as the beginning of the first 
two minutes that were not scored as awake or movement. 
Latencies to each sleep stage were calculated to the first two 
continuous minutes of the stage. Obstructive apneas and 
hypopneas were scored using the criteria from the American 
Academy of Sleep Medicine Task Force.26 Events were scored 
when a .50% decrease (apnea) in airflow, or clear reduction 
(hypopnea) in amplitude of the airflow signal (compared 
with stable breathing during the two minutes preceding the 
event), occurred associated with an arousal, a greater than 3% 
reduction in oxygen saturation (SaO2), or both, and the event 
lasted for at least 10 seconds. Arousals were scored based on 
American Sleep Disorders Association criteria.27 Arousals 
had to be preceded by at least 10 seconds of sleep, have an 
electroencephalogram frequency shift to alpha or theta for at 
least three seconds and up to 15 seconds, and be associated 
with concurrent increased EMG tone in REM sleep. The 
respiratory disturbance index (RDI), which included apneas, 
hypopneas, and snore arousals for the number of events per 
hour of sleep, was calculated. Sleep efficiency (percentage) 
was calculated as the total sleep time divided by the total time 
in bed, multiplied by 100.
Statistical analysis
The completer analysis population was comprised of the 
patients who had initiated quetiapine during the trial and 
had both a baseline and at least one post-baseline PSG 
measurement. Calculation of the sample size was based on 
choosing sleep efficiency as the primary outcome measure 
and estimating that a 15% improvement in sleep efficiency 
would be a clinically meaningful finding in this population. In 
the power calculation, we have used baseline sleep efficiency 
for depressed population to be 67.4 with a standard deviation 
(SD) ± 18.88.28 In order to detect a 15% improvement in sleep 
efficiency using one-sided normal distribution paired t-test 
analysis with a significance of 0.05 and 80% power, a total of 
12 (11.277) patients is required. A sample size of 15 patients 
was used to allow for patient drop out.
Statistical analysis of data was done using the SPSS 17.0.1 
for PC (SPSS Inc, Chicago, IL). Nonparametric analysis using 
the Wilcoxon Signed Rank test for two related samples, com-
paring pre- and post-treatment measures, was used because 
sample sizes were small and often not normally distributed 
(determined by Kolmogorov-Smirnov analysis). In those Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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few pairwise comparisons in which both sets of data were 
normally distributed, additional analysis using two-sided 
normal   distribution paired t-test analysis with a significance 
of 5% was undertaken. Three of the 11 patients missed their 
day 21–28 PSG, one of whom had values substituted from 
their day 42–48 PSG administered during the optional exten-
sion period. An attempt to use multiple regression analysis 
to approximate missed PSG data failed to generate values 
consistent with prior observed values and, thus, for t-tests, 
the last observation was carried forward and substituted for 
missing values.
Results
Sleep efficiency
Quetiapine did not significantly alter sleep efficiency. 
Mean sleep efficiency (± SD) was 69.8% (± 20.6), 78.4% 
(± 9.7), and 74.5% (± 17.4) at baseline, and days 2–4, and 
days 21–28, respectively (P = 0.48 and P = 0.21, Figure 1, 
Table 1).
Sleep continuity
No significant changes in total sleep time (P = 0.18), number 
of awakenings (P = 0.72), time in bed (P = 0.66), and latency 
to sleep onset (P = 0.51) were identified after initiation of 
quetiapine. A significant fall in the RDI was observed after 
2–4 days of quetiapine treatment compared with baseline 
(P = 0.041). However, RDI then increased and there was no 
significant difference in RDI after 21–28 days of quetiapine 
treatment compared with pretreatment initiation (P = 0.86, 
Table 1).
Sleep architecture
Non-REM sleep
Acute quetiapine treatment significantly altered non-REM 
sleep stage characteristics, but longer-term treatment did 
not. The duration of both total Stage 2 sleep (P = 0.016) and 
total non-REM sleep (P = 0.05), as well as the percentage of 
total sleep time in non-REM sleep (P = 0.033) significantly 
increased 2–4 days after treatment initiation, compared with 
baseline, and then decreased towards baseline values. How-
ever, no significant difference in the above sleep measures 
was found between baseline and 21–28 days after treatment 
initiation (Table 1).
After 2–4 days of quetiapine treatment, total time in Stage 1 
sleep (P = 0.16), percentage of total sleep time in Stage 1 sleep 
(P = 0.86), percentage of total sleep time in Stage 2 sleep 
(P = 0.06), percentage of total sleep time in SWS (P = 0.11), 
and total time in SWS (P = 0.20) were not significantly altered. 
After 3–4 weeks of treatment, percentage of total sleep time 
in Stage 1 sleep (P = 0.86), percentage of total sleep time in 
Stage 2 sleep (P = 0.95), total time in Stage 2 sleep (P = 0.86), 
percentage of total sleep time in non-REM sleep (P = 0.44), 
total time in non-REM sleep (P = 0.89), total time in SWS 
(P = 0.48), and percentage of total sleep time in SWS (P = 1.0) 
were not significantly altered compared with baseline measure-
ments (Table 1).
REM sleep
Quetiapine initially altered REM sleep stage characteristics, 
but no significant changes from pretreatment measurements 
were observed after 21–28 days. The percentage of total 
sleep time in REM sleep significantly decreased 2–4 days 
after quetiapine treatment initiation (P = 0.033), although 
there was no significant difference in percentage of total 
sleep time in REM sleep between pretreatment and 3–4 
weeks post-treatment (P = 0.49, Figure 1, Table 2). After 
2–4 days of treatment, there was no significant difference in 
latency to REM sleep (P = 0.86) and total time in REM sleep 
(P = 0.18) compared with pretreatment measurements. Three 
to four weeks of quetiapine treatment did not significantly 
alter latency to REM sleep (P = 0.59), percentage of total 
sleep time in REM sleep (P = 0.49), and total time in REM 
sleep (P = 0.49, Table 1).
Subjective sleep quality
PSQI scores did not significantly change between baseline, 
2–4 days, and 21–28 days after initiation of quetiapine treat-
ment, although PSQI scores tended to decrease over time 
(P > 0.05). After 21–28 days of quetiapine treatment, the 
84
82
80
78
76
74
72
70
68
66
64
62
Baseline
S
l
e
e
p
 
e
f
f
i
c
i
e
n
c
y
 
(
%
)
Day 2–4 Day 21–28
Time
Figure  1  Mean  ±  standard  error  of  sleep  efficiency  (percentage)  over  one 
month of adjunctive quetiapine treatment in 11 subjects. Sleep was assessed by 
polysomnography at baseline, and after 2–4 days and 21–28 days following initiation 
of quetiapine treatment. There was no significant difference in sleep efficiency after 
2–4 days or one month of quetiapine treatment.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Table 2 PSQI scores over one month of quetiapine adjunctive 
treatment in 11 subjects
PSQI sleep 
questionnaire
Baseline 
(Mean ± SD)
Days 2–4 
(Mean ± SD)
Days 21–28 
(Mean ± SD)
Subjective sleep quality 2.5 ± 0.5 1.9 ± 1.0 1.3 ± 0.9*
Sleep latency 2.0 ± 1.2 1.5 ± 1.1 1.4 ± 1.2
Sleep duration 1.2 ± 1.0 1.0 ± 1.1 0.5 ± 0.8
Habitual sleep efficiency 1.9 ± 1.4 1.0 ± 1.2 0.6 ± 1.0
Sleep disturbances 1.9 ± 0.6 1.5 ± 0.5 1.6 ± 0.8
Use of sleep medication 1.2 ± 1.4 1.0 ± 1.3 1.2 ± 1.5
Daytime dysfunction 2.2 ± 0.6 1.8 ± 0.6 1.7 ± 0.9
Total score 12.9 ± 4.1 9.7 ± 4.2 8.4 ± 4.9
Mean score ± SD of each item and total score on PSQI subjective sleep scale. PSQI 
scale was completed by participants at baseline, and after 2–4 days and 21–28 days 
of quetiapine treatment. *P , 0.05 compared with baseline. 
Abbreviations: PSQI, Pittsburg Sleep Quality Index; SD, standard deviation.
Table 1 Sleep continuity and sleep architecture measures over one month of adjunctive quetiapine treatment in 11 subjects
Sleep parameter Baseline Days 2–4 Days 21–28
Mean ± SD Mean ± SD P value Mean ± SD P value
Sleep continuity measure
Time in bed (minutes) 479.4 ± 33.9 471.4 ± 55.1 0.657 478.7 ± 32.3 0.953
Total sleep time (minutes) 332.9 ± 91.0 369.7 ± 63.8 0.182 353.3 ± 70.6 0.859
Sleep efficiency (%) 69.8 ± 20.6 78.4 ± 9.7 0.477 74.5 ± 17.4 0.213
Sleep onset latency (minutes) 67.1 ± 61.5 57.1 ± 51.7 0.508 77.8 ± 78.9 0.515
Number of awakenings 20.6 ± 13.1 23.6 ± 16.0 0.722 22.4 ± 14.1 0.833
RDI 15.9 ± 17.9 12.6 ± 17.9* 0.041 15.5 ± 16.2 0.859
Non-REM measure
Stage 1% TST 11.3 ± 7.9 11.3 ± 6.7 0.859 11.3 ± 7.9 0.859
Stage 2% TST 54.9 ± 14.4 65.8 ± 10.3 0.062 60.0 ± 10.2 0.953
SWS% TST 12.1 ± 9.9 9.3 ± 11.4 0.114 12.2 ± 11.1 1.000
Total non-REM% TST 78.3 ± 17.5 86.3 ± 7.2* 0.033 83.5 ± 9.4 0.441
Stage 1 duration (min) 37.4 ± 26.2 42.2 ± 25.6 0.155 36.8 ± 20.4 0.515
Stage 2 duration (min) 190.3 ± 68.1 244.4 ± 62.1* 0.016 213.8 ± 61.3 0.859
SWS duration (min) 42.9 ± 42.5 33.2 ± 39.9 0.202 41.9 ± 39.3 0.484
Non-REM duration (min) 270.6 ± 91.1 319.8 ± 62.5* 0.050 292.5 ± 54.1 0.889
REM measure
REM latency (minutes) 226.1 ± 111.7 241.5 ± 136.1 0.859 196.9 ± 112.5 0.594
REM% TST 21.7 ± 17.5 13.7 ± 7.2* 0.033 16.5 ± 9.4 0.491
REM duration (minutes) 62.4 ± 33.7 49.9 ± 29.4 0.182 60.8 ± 37.1 0.494
Values are mean and standard deviations. Sleep architecture was assessed by polysomnography at baseline, and at 2–4 days and 21–28 days postinitiation of quetiapine 
treatment. *P # 0.05 compared with baseline. 
Abbreviations: RDI, respiratory disturbance index; TST, total sleep time; SWS, slow wave sleep; REM, rapid eye movement.
subjective sleep quality subscore of the PSQI was signifi-
cantly lower than before treatment (P , 0.05), indicating 
that quetiapine significantly improved subjective sleep quality 
after four weeks. However, there was no significant difference 
in subjective sleep latency, sleep duration, habitual sleep 
efficiency, sleep disturbances, and sleep dysfunction sub-
scores after 2–4 days or 21–28 days of treatment compared 
with baseline, although scores declined with the exception 
of habitual sleep efficiency, which remained unchanged 
(Table 2).
Mood
Quetiapine significantly improved mood and decreased 
depressive symptoms. Total MADRS scores significantly 
declined from baseline to days 2–4 (P = 0.01) and to days 
21–28 (P = 0.008) of quetiapine treatment, to mean scores 
(± SD) of 28.1 (± 7.0), 22.4 (± 7.9), and 14.1 (± 8.4), respec-
tively (Figure 2). Both HDRS and CGI-S total scores signifi-
cantly decreased (P = 0.01 and P = 0.02) from baseline mean 
scores (± SD) of 22.3 (± 4.4) and 4.5 (± 1.2), respectively, to 
mean scores of 12.0 (± 5.8) and 3.2 (± 1.7) after 21–28 days of 
quetiapine treatment (Figures 3 and 4). YMRS mania scores 
remained low and statistically unchanged over time.
Discussion
This study demonstrates that adjunctive quetiapine treatment 
improves self-reported sleep quality, decreases illness sever-
ity, and initially alters sleep architecture in depressed patients. 
Alterations in sleep architecture are no longer seen after a longer 
treatment span. Specifically, quetiapine significantly increased 
total Stage 2 sleep time and total time spent in non-REM sleep, 
as well as decreased the percentage of total sleep time in REM 
sleep and the RDI after 2–4 days of treatment. However, these 
significant effects were not seen after 21–28 days of treatment. 
Depression significantly improved after 3–4 weeks of treatment. 
Therefore, it is evident that quetiapine adjunctive treatment in Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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depressed patients induces changes in sleep architecture that 
are more robust and significant upon acute treatment and tend 
to taper off, approaching pretreatment values after 3–4 weeks 
of treatment. Mood continues to improve over time, with 
illness severity lowest after 3–4 weeks of treatment. These 
results emphasize that quetiapine relieves depressive symptoms 
effectively and rapidly and produces mild sleep benefits, with 
the exception of slightly increasing the number of awakenings 
and decreasing the latency to REM sleep.
Improvements in sleep continuity following quetiapine 
treatment have been observed in individuals who are not 
depressed.21,29 On the first night of treatment, Cohrs et al 
found that quetiapine significantly increased sleep period time, 
total sleep time, and sleep efficiency in healthy individuals.29 
  Moreover, in an open-label trial of patients with insomnia, total 
sleep time and sleep efficiency measured by PSG increased, and 
this increase extended over weeks of quetiapine treatment.21 To 
our knowledge, the current study is the first to investigate sleep 
architecture, as well as observe changes in sleep in depressed 
patients undergoing quetiapine treatment, and in particular, 
patients who are resistant to SSRI treatment. It is important to 
note that pretreatment sleep efficiency values, with a mean of 
69.8 ± 20.6%, in this study are comparable with those of other 
PSG studies in depressed patients (67.4 ± 18.9%),28 indicating 
that there was no selection bias regarding the baseline sleep 
quality of participants in this study.
The effects of atypical antipsychotics on sleep architecture 
in depressed patients are not well documented. However, 
similar improvements in sleep following quetiapine treat-
ment are also observed in the few other antipsychotics that 
have been studied. Adjunctive olanzapine treatment improves 
sleep continuity as well as increases percentage of sleep time 
in both non-REM sleep and SWS sleep in treatment-resistant 
patients with MDD.30 Risperidone decreases REM sleep and 
increases Stage 2 sleep in SSRI-resistant depressed patients.31 
This study shows that quetiapine increases non-REM sleep, as 
does olanzapine, in addition to increasing Stage 2 sleep and 
decreasing REM sleep, as does risperidone. Quetiapine appears 
to alter sleep architecture initially in a manner similar to other 
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Figure 2 Mean ± standard error of the MADRS score over one month of adjunctive 
quetiapine  treatment  in  11  subjects.  MADRS  score  was  assessed  at  baseline, 
after acute treatment (2–4 days), and after longer-term treatment (21–28 days) 
with quetiapine. After 2–4 days and 21–28 days of quetiapine treatment, MADRS 
scores significantly decreased from baseline measurements (P = 0.01 and P = 0.008, 
respectively). *P , 0.05 compared with baseline. 
Abbreviation: MADRS, Montgomery Asperg Depression Rating Scale.
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Figure 3 Mean ± standard error of the HDRS score over one month of quetiapine 
adjunctive treatment in 11 subjects. HDRS-17 score was assessed at baseline, after 
acute treatment (2–4 days), and after longer-term treatment (21–28 days) with 
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Figure 4 Mean ± standard error of the CGI-S score over one month of quetiapine 
adjunctive treatment in 11 subjects. CGI-S score was assessed at baseline, after acute 
treatment (2–4 days) and after longer-term treatment (21–28 days) with quetiapine. 
After 21–28 days of quetiapine treatment, CGI-S scores significantly decreased from 
baseline measurements (P = 0.02). *P , 0.05 compared with baseline. 
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medications in its class; however, unlike treatment with other 
antipsychotics, these improvements in sleep do not last.
Of particular interest is the finding that quetiapine sup-
pressed REM sleep, as identified by decreased percentage 
of REM sleep. Depression is associated with REM sleep 
abnormalities including decreased REM latency, increased 
REM density, and increased REM time.32,33 It is possible 
that an initial decrease in REM sleep may be related to acute 
improvements in mood following quetiapine treatment; 
however, longer-term improvements in depressive symp-
tomatology are not related to changes in sleep.
The sleep-inducing properties of quetiapine are most 
likely related to the medication’s receptor-binding profile. 
Quetiapine is an antagonist at H1 receptors, inducing sleep 
upon inhibition of histamine synthesis. Histaminergic activ-
ity has more recently been implicated in the development of 
depression. Patients with depression show a decrease in H1 
receptor binding, and this decrease is correlated with illness 
severity.34 Therefore, the modulation of histaminergic activity 
by quetiapine to induce sleep may be related to the reduction 
of depressive symptoms in these patients.
The most substantial changes in sleep occurred after 
2–4 days of treatment, after which these changes began to 
decline, yet patients experienced the greatest improvement 
in mood after 21–28 days of quetiapine treatment. This 
leads us to conclude that, while psychotropic medications 
may act to reduce depressive symptoms by improving the 
sleep of patients with depression or bipolar disorder, sleep 
improvements are only a part of the medication’s therapeutic 
action. Improvements in sleep contribute to a therapeutic 
response, but do not account on their own for the reduc-
tion in depressive symptomatology seen after quetiapine 
treatment.
The main limitations in this study are its open-label design, 
small sample size, lack of a control group, and a study popula-
tion of predominantly women. Furthermore, sleep studies such 
as this one, acquire PSG data at distinct time points which may 
not be representative of the entire week. This study should be 
repeated as a randomized, placebo-controlled, double-blind 
assessment study with a larger sample size.
Conclusion
Acute quetiapine adjunctive therapy alters sleep architecture in 
depressed patients, after which these changes taper off towards 
baseline levels and are not significantly present after longer-
term treatment. This pilot study suggests that further investiga-
tion of the effect of quetiapine on sleep architecture is warranted 
in patients experiencing a major depressive episode.
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